Why the study?
Does chloroquine block mutant Kir2.1 channels and normalize repolarization properties in models of Short QT Syndrome?
Does chloroquine block mutant Kir2.1 channels and normalize repolarization properties in models of Short QT Syndrome?
Chloroquine blocks mutant Kir2.1 channels and normalizes repolarization in silico, suggesting it may be a potential therapy for Short QT Syndrome type 3.
Merits further preclinical testing in Short QT syndrome type 3; leaves open clinical translation from animal and in silico data.
Short QT Syndrome (SQTS) is a novel clinical entity characterized by markedly rapid cardiac repolarization and lethal arrhythmias. A mutation in the Kir2.1 inward rectifier K+ channel (D172N) causes one form of SQTS (SQT3). Pharmacologic block of Kir2.1 channels may hold promise as potential therapy for SQT3. We recently reported that the anti-malarial drug chloroquine blocks Kir2.1 channels by plugging the cytoplasmic pore domain. In this study, we tested whether chloroquine blocks D172N Kir2.1 channels in a heterologous expression system and if chloroquine normalizes repolarization properties using a mathematical model of a human ventricular myocyte. Chloroquine caused a dose- and voltage-dependent reduction in wild-type (WT), D172N and WT-D172N heteromeric Kir2.1 current. The potency and kinetics of chloroquine block of D172N and WT-D172N Kir2.1 current were similar to WT. In silico modeling of the heterozygous WT-D172N Kir2.1 condition predicted that 3 microM chloroquine normalized inward rectifier K+ current magnitude, action potential duration and effective refractory period. Our results suggest that therapeutic concentrations of chloroquine might lengthen cardiac repolarization in SQT3.
No takes yet. Share an insight, caveat, or question.
López-Izquierdo et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: